All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
CC-93269 is a humanized 2+1 IgG T cell engager that binds bivalently to B-cell maturation antigen (BCMA) on myeloma cells and monovalently to CD3ε on T cells, leading to T cell activation and myeloma cell death.1
At the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, Luciano J. Costa, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, US reported the interim results from the phase I dose-finding study, CC-93269-MM-001 (NCT03486067), that evaluated CC-93269 in patients with relapsed/refractory multiple myeloma (RRMM).2
Subscribe to get the best content related to multiple myeloma delivered to your inbox